Literature DB >> 30299457

Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS.

Giorgio Grani1, Livia Lamartina1, Valeria Ascoli2, Daniela Bosco2, Marco Biffoni3, Laura Giacomelli3, Marianna Maranghi1, Rosa Falcone1, Valeria Ramundo1, Vito Cantisani4, Sebastiano Filetti1, Cosimo Durante1.   

Abstract

Context: The prevalence of thyroid nodules in the general population is increasingly high, and at least half of those biopsied prove to be benign. Sonographic risk-stratification systems are being proposed as "rule-out" tests that can identify nodules that do not require fine-needle aspiration (FNA) cytology. Objective: To comparatively assess the performances of five internationally endorsed sonographic classification systems [those of the American Thyroid Association, the American Association of Clinical Endocrinologists, the American College of Radiology (ACR), the European Thyroid Association, and the Korean Society of Thyroid Radiology] in identifying nodules whose FNAs can be safely deferred and to estimate their negative predictive values (NPVs). Design: Prospective study of thyroid nodules referred for FNA. Setting: Single academic referral center. Patients: Four hundred seventy-seven patients (358 females, 75.2%); mean (SD) age, 55.9 (13.9) years. Main Outcome Measures: Number of biopsies classified as unnecessary, false-negative rate (FNR), sensitivity, specificity, predictive values, and diagnostic ORs for each system.
Results: Application of the systems' FNA criteria would have reduced the number of biopsies performed by 17.1% to 53.4%. The ACR Thyroid Imaging Reporting and Data System (TIRADS) allowed the largest reduction (268 of 502) with the lowest FNR (NPV, 97.8%; 95% CI, 95.2% to 99.2%). Except for the Korean Society of Thyroid Radiology TIRADS, all other systems exhibited significant discriminatory performance but produced significantly smaller reductions in the number of procedures. Conclusions: Internationally endorsed sonographic risk stratification systems vary widely in their ability to reduce the number of unnecessary thyroid nodule FNAs. The ACR TIRADS outperformed the others, classifying more than half the biopsies as unnecessary with a FNR of 2.2%.

Entities:  

Mesh:

Year:  2019        PMID: 30299457     DOI: 10.1210/jc.2018-01674

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  52 in total

1.  Comparison and preliminary discussion of the reasons for the differences in diagnostic performance and unnecessary FNA biopsies between the ACR TIRADS and 2015 ATA guidelines.

Authors:  Xiao-Li Wu; Jia-Rui Du; Hui Wang; Chun-Xiang Jin; Guo-Qing Sui; Dong-Yan Yang; Yuan-Qiang Lin; Qiang Luo; Ping Fu; He-Qun Li; Deng-Ke Teng
Journal:  Endocrine       Date:  2019-03-04       Impact factor: 3.633

2.  Comparison among TIRADS (ACR TI-RADS and KWAK- TI-RADS) and 2015 ATA Guidelines in the diagnostic efficiency of thyroid nodules.

Authors:  Luying Gao; Xuehua Xi; Yuxin Jiang; Xiao Yang; Ying Wang; Shenling Zhu; Xingjian Lai; Xiaoyan Zhang; Ruina Zhao; Bo Zhang
Journal:  Endocrine       Date:  2019-01-18       Impact factor: 3.633

3.  Computer-aided diagnostic system for thyroid nodule sonographic evaluation outperforms the specificity of less experienced examiners.

Authors:  Daniele Fresilli; Giorgio Grani; Maria Luna De Pascali; Gregorio Alagna; Eleonora Tassone; Valeria Ramundo; Valeria Ascoli; Daniela Bosco; Marco Biffoni; Marco Bononi; Vito D'Andrea; Fabrizio Frattaroli; Laura Giacomelli; Yana Solskaya; Giorgia Polti; Patrizia Pacini; Olga Guiban; Raffaele Gallo Curcio; Marcello Caratozzolo; Vito Cantisani
Journal:  J Ultrasound       Date:  2020-04-03

4.  Sonographic features of follicular variant of papillary thyroid carcinoma (FV-PTC) and diagnostic performance of the 2017 ACR TI-RADS in FV-PTC.

Authors:  Fan Zhang; Wen Chen
Journal:  Endocrine       Date:  2020-01-09       Impact factor: 3.633

5.  Use of the Thyroid Imaging Reporting and Data System (TIRADS) in clinical practice: an Italian survey.

Authors:  Giovanni Mauri; Salvatore Gitto; Vito Cantisani; Gianfranco Vallone; Cosima Schiavone; Enrico Papini; Luca Maria Sconfienza
Journal:  Endocrine       Date:  2020-01-25       Impact factor: 3.633

6.  Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference.

Authors:  Pierpaolo Trimboli; Marco Castellana; Camilla Virili; Roald Flesland Havre; Fabiano Bini; Franco Marinozzi; Ferdinando D'Ambrosio; Francesco Giorgino; Luca Giovanella; Helmut Prosch; Giorgio Grani; Maija Radzina; Vito Cantisani
Journal:  Radiol Med       Date:  2020-01-22       Impact factor: 3.469

7.  Validation and comparison of three newly-released Thyroid Imaging Reporting and Data Systems for cancer risk determination.

Authors:  Ting Xu; Ya Wu; Run-Xin Wu; Yu-Zhi Zhang; Jing-Yu Gu; Xin-Hua Ye; Wei Tang; Shu-Hang Xu; Chao Liu; Xiao-Hong Wu
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

8.  Investigating the Effect of Thyroid Nodule Location on the Risk of Thyroid Cancer.

Authors:  Sina Jasim; Thomas J Baranski; Sharlene A Teefey; William D Middleton
Journal:  Thyroid       Date:  2020-01-28       Impact factor: 6.568

9.  Comparison of different systems of ultrasound (US) risk stratification for malignancy in elderly patients with thyroid nodules. Real world experience.

Authors:  Fernando Di Fermo; Noelia Sforza; Melanie Rosmarin; Yanina Morosan Allo; Carina Parisi; Jimena Santamaria; Nestor Pacenza; Carlos Zuk; Cristina Faingold; Florencia Ferraro; Tomas Meroño; Gabriela Brenta
Journal:  Endocrine       Date:  2020-04-14       Impact factor: 3.633

10.  Diagnostic performance rates of the ACR-TIRADS and EU-TIRADS based on histopathological evidence.

Authors:  İlhan Hekimsoy; Egemen Öztürk; Yeşim Ertan; Mehmet Nurullah Orman; Gülgün Kavukçu; Ahmet Gökhan Özgen; Murat Özdemir; Süha Süreyya Özbek
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.